NCT06042647View on ClinicalTrials.gov

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions
Psoriasis Vulgaris
Interventions
DRUG

0.01% Halobetasol

Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.

DRUG

0.045% Tazarotene

Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.

DRUG

0.05% Clobetasol Propionate

Drug to be applied to designated psoriatic plaque at bedtime.

Trial Locations (1)

27262

Dermatology Consulting Services, PLLC, High Point

All Listed Sponsors
lead

Dermatology Consulting Services, PLLC

NETWORK